# US 2006/0068389 A1 · Methods and compositions for inhibiting hiv replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0068389 A1
- Document ID: US20060068389A1
- Status: Published application
- Kind: A1
- Application number: 10/515,327
- Filed: 2003-05-23
- Published: 2006-03-30
- Earliest claimed: 2002-05-24
- Inventors: David Weiner
- Web page: https://patentgrep.com/patent/US20060068389A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/569: substituted in position 17 alpha, e.g. ethisterone
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutial composition comprising compounds and/or compositions useful to inhibit HIV replication are disclosed. Methods of treating individuals infected with HIV are disclosed. Methods of preventing HIV infection in high-risk individuals are disclosed.

## Claims

### Claim 1

A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and, a compound having a structure selected from the group consisting of Formula D1, Formula D2, Formula D3, Formula D4 and pharmaceutically acceptable salts thereof and/or Composition D5.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 comprising Compound D1.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 comprising Compound D2.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1 comprising Compound D3.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1 comprising Compound D4.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1 comprising Composition D5.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6 further comprising a compound having a structure selected from the group consisting: mifepristone, nucleoside and non-nucleoside RT inhibitors (lamivudine, didanosine, abacavir, stavudine, zalcitabine, efavirenz, nevirapine, and delavirdine), protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), and fusion inhibitors (T-20 and T-1249) as well as acyclovir, ganciclovir, foscarnet, interferon alpha-2a, and interferon alpha-2b.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1 comprising: a pharmaceutically acceptable carrier or diluent; and, a compound having a structure selected from the group consisting of Formula D1, Formula D2, Formula D3, Formula D4 and pharmaceutically acceptable salts thereof and further comprising a compound having a structure selected from the group consisting: mifepristone, nucleoside and non-nucleoside RT inhibitors (zidovudine, lamivudine, didanosine, abacavir, stavudine, zalcitabine, efavirenz, nevirapine, and delavirdine), protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), and fusion inhibitors (T-20 and T-1249) as well as acyclovir, ganciclovir, foscarnet, interferon alpha-2a, and interferon alpha-2b.

### Claim 9 (depends on 1)

A method of treating an individual who is infected with HIV comprising the step of administering to said individual a therapeutically effective amount of a composition according to claim 1.

### Claim 10 (depends on 1)

A method of preventing HIV infection in an individual identified as being a high risk individual, the method comprising the step of administering to said individual a prophylactically effective amount of a composition according to claim 1.
